Cell-Mediated Inflammatory Pathway and Diabetic Retinopathy-Administrative Supplement
细胞介导的炎症途径和糖尿病视网膜病变-管理补充剂
基本信息
- 批准号:10789444
- 负责人:
- 金额:$ 14.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:Administrative SupplementAdvanced DevelopmentApoptosisApoptoticBiological MarkersBiomedical ResearchCapillary Endothelial CellCellsDataDiabetes MellitusDiabetic RetinopathyDiseaseDoctor of PhilosophyEndothelial CellsEnsureEtiologyEventEyeEye diseasesGenesGrantHispanicHuman CloningIndividualInduction of ApoptosisInflammatoryInstitutionalizationIntegrinsInterventionKnowledgeLearningMacrophageMediatingMembraneMentorsMentorshipMinority GroupsMolecularOutcomeParentsPathologyPathway interactionsPericytesPrediabetes syndromeProgram EvaluationProteinsRegulationReproducibilityResearchResearch Project GrantsRetinaRoleSignaling ProteinStudentsTGFBI geneTalentsTherapeutic InterventionTrainingTraining ProgramsTransforming Growth Factor betaUnited States National Institutes of Healthangiogenesisdiabeticeducation researchequity, diversity, and inclusionexperienceexperimental studyfaculty mentorgraduate studentinnovationinterestmonocytenovelpandemic diseasepeer coachingprogramsreceptorresponsesuccesstherapeutic targettimelineundergraduate student
项目摘要
Abstract:
Retinal pericytes are contractile cells adjacent to and provide support for endothelial cells of
capillaries, which are essential in the regulation of retinal vasculature in the eye. Early stages of
diabetic retinopathy are characterized by the loss of retinal pericytes, which lead to the
development of advanced-stage pathology including angiogenesis. Although much is known
about the etiology of diabetic retinopathy, the apoptotic pathway that incites retinal pericyte loss
remains unclear. Our preliminary studies reveal that monocyte-derived macrophages secrete
TGFβ1, which induces the expression and secretion of a TGFβ1-Induced, pro- apoptotic BIGH3
protein (TGFβ –Induced Gene Human Clone 3) leading to apoptosis of endothelial cells and
retinal pericytes. This cascade of events has been attributed to the primary cause of retinal
pericyte apoptosis and diabetic retinopathy. Macrophage TGF-β1 and BIGH3 are prediabetic
biomarkers, and potential therapeutic targets for intervention of diabetic retinopathy for diabetic
individuals. In the present study, we hypothesize that a similar macrophage-TGFβ–BIGH3
pathway may induce apoptosis in retinal pericytes. We will investigate the interaction between
endothelial cells and retinal pericytes, as well as macrophages’ role on retinal pericyte expression
of BIGH3 in response to TGFβ, and retinal pericyte apoptosis. Furthermore, we will also study
the association of BIGH3 with integrin, a trans-membrane signaling protein receptor and its role
to mediate retinal pericyte apoptosis. This novel study focuses on macrophage-mediated
molecular pathway to impact diabetic retinopathy and it will provide opportunities of therapeutic
intervention of this ocular eye disorder. Student trainees will be involved in these research
projects, providing valuable experience on biomedical research.
摘要:
视网膜周细胞是与视网膜血管内皮细胞相邻的可收缩细胞,
毛细血管,其在眼睛中的视网膜血管系统的调节中是必需的。初期
糖尿病性视网膜病变的特征在于视网膜周细胞的损失,这导致了
包括血管生成在内的晚期病理学的发展。虽然我们知道
关于糖尿病视网膜病变的病因,引发视网膜周细胞损失的凋亡途径,
仍不清楚我们的初步研究表明,单核细胞衍生的巨噬细胞分泌
TGFβ1,其诱导TGFβ1诱导的促凋亡BIGH 3的表达和分泌
蛋白质(TGFβ诱导基因人克隆3)导致内皮细胞凋亡,
视网膜周细胞这一系列事件被归因于视网膜病变的主要原因。
周细胞凋亡与糖尿病视网膜病变的关系巨噬细胞TGF-β1和BIGH 3是糖尿病前期
糖尿病视网膜病变的生物标志物和潜在的治疗靶点
个体在本研究中,我们假设一个类似的巨噬细胞-TGF β-BIGH 3
途径可能诱导视网膜周细胞凋亡。我们将研究
内皮细胞和视网膜周细胞,以及巨噬细胞对视网膜周细胞表达的作用
BIGH 3对TGFβ的反应以及视网膜周细胞凋亡。此外,我们还将研究
BIGH 3与跨膜信号蛋白受体整合素结合及其作用
介导视网膜周细胞凋亡。这项新的研究重点是巨噬细胞介导的
分子途径影响糖尿病视网膜病变,它将提供机会,
这种眼部疾病的干预。实习生将参与这些研究
项目,为生物医学研究提供宝贵经验。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW T C TSIN其他文献
ANDREW T C TSIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW T C TSIN', 18)}}的其他基金
Cell-Meditated Inflammatory Pathway and Diabetic Retinopathy
细胞介导的炎症途径和糖尿病视网膜病变
- 批准号:
10368669 - 财政年份:2022
- 资助金额:
$ 14.28万 - 项目类别:
Cell-Mediated Inflammatory Pathway and Diabetic Retinopathy-Administrative Supplement
细胞介导的炎症途径和糖尿病视网膜病变-管理补充剂
- 批准号:
10604916 - 财政年份:2022
- 资助金额:
$ 14.28万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 14.28万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 14.28万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 14.28万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 14.28万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 14.28万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 14.28万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 14.28万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 14.28万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 14.28万 - 项目类别:














{{item.name}}会员




